S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
BABA   182.48 (-2.40%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
BAC   32.79 (-0.91%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
BABA   182.48 (-2.40%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
BAC   32.79 (-0.91%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
BABA   182.48 (-2.40%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
BAC   32.79 (-0.91%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
BABA   182.48 (-2.40%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
BAC   32.79 (-0.91%)
Log in

Crinetics Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:CRNX)

$19.18
+0.27 (+1.43 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$18.36
Now: $19.18
$19.52
50-Day Range
$14.91
MA: $16.94
$19.23
52-Week Range
$14.33
Now: $19.18
$36.95
Volume73,891 shs
Average Volume63,450 shs
Market Capitalization$464.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.88
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.43 million
Book Value$6.67 per share

Profitability

Net Income$-27,110,000.00
Net Margins-1,303.31%

Miscellaneous

Employees47
Market Cap$464.16 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.03. The firm earned $0.51 million during the quarter, compared to the consensus estimate of $0.33 million. Crinetics Pharmaceuticals had a negative return on equity of 24.12% and a negative net margin of 1,303.31%. View Crinetics Pharmaceuticals' Earnings History.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

What price target have analysts set for CRNX?

3 equities research analysts have issued 1 year target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $40.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $34.33 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (10/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

Headlines about CRNX stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Crinetics Pharmaceuticals.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,970,000 shares, an increase of 5.3% from the August 30th total of 1,870,000 shares. Based on an average trading volume of 69,200 shares, the days-to-cover ratio is presently 28.5 days. Currently, 14.2% of the company's stock are short sold. View Crinetics Pharmaceuticals' Current Options Chain.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the folowing people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Alps Advisors Inc. (0.20%) and Tower Research Capital LLC TRC (0.01%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Crinetics Pharmaceuticals.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Ventures Iv LP 5Am and Vivo Capital Fund Viii, LP. View Insider Buying and Selling for Crinetics Pharmaceuticals.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC . Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $19.18.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $464.16 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel